Last reviewed · How we verify

Albireo — Portfolio Competitive Intelligence Brief

Albireo pipeline: 1 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Questran Questran marketed Other
A4250 (odevixibat) A4250 (odevixibat) phase 3 Bile acid transporter inhibitor IBAT (ileal bile acid transporter; SLC10A2) Hepatology / Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Centre Hospitalier Universitaire de Nice · 1 shared drug class
  2. Genzyme, a Sanofi Company · 1 shared drug class
  3. HealthPartners Institute · 1 shared drug class
  4. Hospices Civils de Lyon · 1 shared drug class
  5. Taejoon Pharmaceutical Co., Ltd. · 1 shared drug class
  6. University Hospital, Gentofte, Copenhagen · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Albireo:

Cite this brief

Drug Landscape (2026). Albireo — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/albireo. Accessed 2026-05-15.

Related